| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Genome polyprotein, Capsid protein C, Capsid protein, Core protein, Protein prM, Precursor membrane protein, Peptide pr, Peptide precursor, Small envelope protein M, Matrix protein, Envelope protein E, Non-structural protein 1, NS1, Non-structural protein 2A, NS2A, Serine protease subunit NS2B, Flavivirin protease NS2B regulatory subunit, Non-structural protein 2B, Serine protease NS3, EC:3.4.21.91, EC:3.6.1.15, EC:3.6.4.13, Flavivirin protease NS3 catalytic subunit, Non-structural protein 3, Non-structural protein 4A, NS4A, Peptide 2k, Non-structural protein 4B, NS4B, RNA-directed RNA polymerase NS5, EC:2.1.1.56, EC:2.1.1.57, EC:2.7.7.48, NS5 |
| Clonality | |
| Form | Liquid |
| Host | |
| Isotype | |
| Product Type | |
| Purity | |
| Reactivity | |
| Storage | |
| Target |
Overview
Antibody against Zika Virus Envelope protein E (Precursor membrane protein) for research detection of protein expression and localization.
Target biology
ZIKA is a molecular target commonly interrogated by antibody-based methods to measure protein expression, localization and regulation across biological systems. Antibodies against ZIKA support studies ranging from baseline expression profiling to stimulus- or disease-associated changes in abundance and subcellular distribution. For pathway-level interpretation, pair ZIKA detection with appropriate controls and complementary readouts (e.g., genetic perturbation or orthogonal assays).
Expected localization
Subcellular localization is target- and context-dependent; use cell-type appropriate controls and, where possible, genetic KO/KD as specificity controls.
Research context
This target is frequently studied in the context of Infectious Disease research. Application suitability (e.g., ELISA, WB, FCM) is indicated in the specifications; conditions should be optimized by titration. Species reactivity information is provided in the specifications (reported: Zika Virus).
Recommended experimental notes
- For Western blotting, optimize lysis conditions and include reducing/non-reducing conditions as appropriate; titrate antibody to balance sensitivity and background.
- For ELISA, ensure capture/detection antibody compatibility and run a standard curve; verify sample matrix effects with spike-and-recovery and dilution linearity.
Controls & interpretation
Where possible, confirm specificity using genetic perturbation (KO/KD/CRISPR), peptide competition (if applicable), or an orthogonal readout. Include a negative control sample expected to express low/none of Zika Virus Envelope protein E, and a positive control sample known to express Zika Virus Envelope protein E.
For research use only. Not for diagnostic procedures.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.